Biotechnology

Neuroscience

Receptor

In vivo

Agonist

Dopamine receptor D2

Cell culture

Biology

Dopamine receptor D1

Dopamine receptor

Dopaminergic

Endogenous agonist

Neurotrophic factors

Chemistry

Glial cell line-derived neurotrophic factor

In vitro

Brain-derived neurotrophic factor

Dopamine agonist

Dopamine

Genetics

Biochemistry

Pharmacology

Movement Disorders

Motor symptoms of Parkinson's disease (PD) are caused by degeneration and progressive loss of nigrostriatal dopamine neurons. Currently, no cure for this disease is available. Existing drugs alleviate PD symptoms but fail to halt neurodegeneration. Glial cell line-derived neurotrophic factor (GDNF) is able to protect and repair dopamine neurons in vitro and in animal models of PD, but the clinical use of GDNF is complicated by its pharmacokinetic properties. The present study aimed to evaluate the neuronal effects of a blood-brain-barrier penetrating small molecule GDNF receptor Rearranged in Transfection agonist, BT13, in the dopamine system.

Glial Cell Line–Derived Neurotrophic Factor Receptor Rearranged During Transfection Agonist Supports Dopamine Neurons<i>In Vitro</i>and Enhances Dopamine Release<i>In Vivo</i>

Glial Cell Line–Derived Neurotrophic Factor Receptor Rearranged During Transfection Agonist Supports Dopamine NeuronsIn Vitroand Enhances Dopamine ReleaseIn Vivo